Cargando…
Broad immunity to SARS-CoV-2 variants of concern mediated by a SARS-CoV-2 receptor-binding domain protein vaccine
BACKGROUND: The SARS-CoV-2 global pandemic has fuelled the generation of vaccines at an unprecedented pace and scale. However, many challenges remain, including: the emergence of vaccine-resistant mutant viruses, vaccine stability during storage and transport, waning vaccine-induced immunity, and co...
Ejemplares similares
-
377. Phase I trial of two novel SARS-CoV-2 beta variant receptor-binding domain recombinant protein and mRNA vaccines as 4th dose boosters
por: Nolan, Terry, et al.
Publicado: (2023) -
Air-Liquid-Interface Differentiated Human Nose Epithelium: A Robust Primary Tissue Culture Model of SARS-CoV-2 Infection
por: Tran, Bang M., et al.
Publicado: (2022) -
Simultaneous evaluation of antibodies that inhibit SARS-CoV-2 variants via multiplex assay
por: Lopez, Ester, et al.
Publicado: (2021) -
Susceptibility of Wild Canids to SARS-CoV-2
por: Porter, Stephanie M., et al.
Publicado: (2022) -
A point-of-care lateral flow assay for neutralising antibodies against SARS-CoV-2
por: Fulford, Thomas S., et al.
Publicado: (2021)